Loading…
Loading…
VRTX · NASDAQ · Healthcare
“When you find a company with a moat as wide as Vertex's cystic fibrosis franchise, paying thirty times earnings isn't unreasonable for such rare medicine-making excellence.”
— In the voice of Buffett
Determine what growth rate the market is pricing in. Compare implied growth against historical performance to identify mispricing.
Market Cap
$114.58B
P/E Ratio
28.98
Forward P/E
—
EPS
$15.46
PEG Ratio
0.88
Book Value
$73.00
Dividend Yield
—
Profit Margin
32.94%
ROE
21.18%
Use the interactive reverse dcf with pre-loaded data for Vertex Pharmaceuticals Inc. Adjust discount rates, growth assumptions, and projection horizons to model different scenarios.
Pre-loaded inputs for VRTX: